TopiVert
London
About TopiVert
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2016)
- Website: topivert.com
- Phone: [email protected]
Industries & Categories
Angel Investment, Biotechnology, Health Care, Management Information Systems
Social Profiles
Canonical: https://fsome.com/organization/topivert-3089217 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.